Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naven Chetty

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Asia-Pacific Journal of Clinical Oncology|March 22, 2016
Indigenous Australians with non-small cell lung cancer or cervical cancer receive suboptimal treatmentLisa J Whop, Christina M Bernardes, Srinivas Kondalsamy-Chennakesavan, et al.
NPJ Precision Oncology|December 7, 2023
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibitionAsmerom T Sengal, Vanessa Bonazzi, Deborah Smith, et al.
Gynecologic Oncology|February 28, 2012
Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancerSrinivas Kondalsamy-Chennakesavan, Changhong Yu, Michael W Kattan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2020
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancerShih-Ern Yao, Lee Tripcony, Karen Sanday, et al.
Gynecologic Oncology|April 2, 2015
Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trialJannah Baker, Monika Janda, Nick Graves, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|July 19, 2017
The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomesJames L Nicklin, Shaun McGrath, Lee Tripcony, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|June 1, 2023
Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian contextArthur Samoylovich, Bronwyn Jennings, Catherine Shannon, et al.
Biomaterials|August 11, 2019
Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenograftsAli Shokoohmand, Jiongyu Ren, Jeremy Baldwin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 10, 2025
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapyLouisa Alim, Siddharth Adityan, Rui Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 23, 2026
Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived ModelsNihar Godbole, Andrew Lai, Alexander Quinn, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Asia-Pacific Journal of Clinical Oncology|March 22, 2016
Indigenous Australians with non-small cell lung cancer or cervical cancer receive suboptimal treatmentLisa J Whop, Christina M Bernardes, Srinivas Kondalsamy-Chennakesavan, et al.
NPJ Precision Oncology|December 7, 2023
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibitionAsmerom T Sengal, Vanessa Bonazzi, Deborah Smith, et al.
Gynecologic Oncology|February 28, 2012
Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancerSrinivas Kondalsamy-Chennakesavan, Changhong Yu, Michael W Kattan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2020
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancerShih-Ern Yao, Lee Tripcony, Karen Sanday, et al.
Gynecologic Oncology|April 2, 2015
Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trialJannah Baker, Monika Janda, Nick Graves, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|July 19, 2017
The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomesJames L Nicklin, Shaun McGrath, Lee Tripcony, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|June 1, 2023
Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian contextArthur Samoylovich, Bronwyn Jennings, Catherine Shannon, et al.
Biomaterials|August 11, 2019
Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenograftsAli Shokoohmand, Jiongyu Ren, Jeremy Baldwin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 10, 2025
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapyLouisa Alim, Siddharth Adityan, Rui Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 23, 2026
Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived ModelsNihar Godbole, Andrew Lai, Alexander Quinn, et al.
Pageof 4